208 related articles for article (PubMed ID: 12920584)
21. Exosomes mediate Coxsackievirus B3 transmission and expand the viral tropism.
Fu Y; Xiong S
PLoS Pathog; 2023 Jan; 19(1):e1011090. PubMed ID: 36634130
[TBL] [Abstract][Full Text] [Related]
22. More recent swine vesicular disease virus isolates retain binding to coxsackie-adenovirus receptor, but have lost the ability to bind human decay-accelerating factor (CD55).
Jimenez-Clavero MA; Escribano-Romero E; Ley V; Spiller OB
J Gen Virol; 2005 May; 86(Pt 5):1369-1377. PubMed ID: 15831949
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of coxsackievirus infection in cardiomyocytes by small dsRNA targeting its cognate coxsackievirus adenovirus receptor.
Sharma M; Mishra B; Saikia UN; Bahl A; Ratho RK
Indian J Med Res; 2017 Oct; 146(4):520-527. PubMed ID: 29434067
[TBL] [Abstract][Full Text] [Related]
24. Variations of coxsackievirus B3 capsid primary structure, ligands, and stability are selected for in a coxsackievirus and adenovirus receptor-limited environment.
Carson SD; Chapman NM; Hafenstein S; Tracy S
J Virol; 2011 Apr; 85(7):3306-14. PubMed ID: 21270163
[TBL] [Abstract][Full Text] [Related]
25. The role of B lymphocytes in coxsackievirus B3 infection.
Mena I; Perry CM; Harkins S; Rodriguez F; Gebhard J; Whitton JL
Am J Pathol; 1999 Oct; 155(4):1205-15. PubMed ID: 10514403
[TBL] [Abstract][Full Text] [Related]
26. Virus receptor trap neutralizes coxsackievirus in experimental murine viral myocarditis.
Lim BK; Choi JH; Nam JH; Gil CO; Shin JO; Yun SH; Kim DK; Jeon ES
Cardiovasc Res; 2006 Aug; 71(3):517-26. PubMed ID: 16806133
[TBL] [Abstract][Full Text] [Related]
27. A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells.
Shafren DR; Williams DT; Barry RD
J Virol; 1997 Dec; 71(12):9844-8. PubMed ID: 9371658
[TBL] [Abstract][Full Text] [Related]
28. Single-Point Mutations within the Coxsackie B Virus Receptor-Binding Site Promote Resistance against Soluble Virus Receptor Traps.
Pinkert S; Kopp A; Brückner V; Fechner H; Beling A
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669334
[TBL] [Abstract][Full Text] [Related]
29. Dynamin- and lipid raft-dependent entry of decay-accelerating factor (DAF)-binding and non-DAF-binding coxsackieviruses into nonpolarized cells.
Patel KP; Coyne CB; Bergelson JM
J Virol; 2009 Nov; 83(21):11064-77. PubMed ID: 19710132
[TBL] [Abstract][Full Text] [Related]
30. Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells.
Funke C; Farr M; Werner B; Dittmann S; Überla K; Piper C; Niehaus K; Horstkotte D
J Gen Virol; 2010 Aug; 91(Pt 8):1959-1970. PubMed ID: 20392896
[TBL] [Abstract][Full Text] [Related]
31. Interaction with decay-accelerating factor facilitates coxsackievirus B infection of polarized epithelial cells.
Shieh JT; Bergelson JM
J Virol; 2002 Sep; 76(18):9474-80. PubMed ID: 12186929
[TBL] [Abstract][Full Text] [Related]
32. Highly variable expression of virus receptors in the human cardiovascular system. Implications for cardiotropic viral infections and gene therapy.
Poller W; Fechner H; Noutsias M; Tschoepe C; Schultheiss HP
Z Kardiol; 2002 Dec; 91(12):978-91. PubMed ID: 12490988
[TBL] [Abstract][Full Text] [Related]
33. Human coxsackie-adenovirus receptor is colocalized with integrins alpha(v)beta(3) and alpha(v)beta(5) on the cardiomyocyte sarcolemma and upregulated in dilated cardiomyopathy: implications for cardiotropic viral infections.
Noutsias M; Fechner H; de Jonge H; Wang X; Dekkers D; Houtsmuller AB; Pauschinger M; Bergelson J; Warraich R; Yacoub M; Hetzer R; Lamers J; Schultheiss HP; Poller W
Circulation; 2001 Jul; 104(3):275-80. PubMed ID: 11457744
[TBL] [Abstract][Full Text] [Related]
34. Clinical coxsackievirus B isolates differ from laboratory strains in their interaction with two cell surface receptors.
Bergelson JM; Modlin JF; Wieland-Alter W; Cunningham JA; Crowell RL; Finberg RW
J Infect Dis; 1997 Mar; 175(3):697-700. PubMed ID: 9041347
[TBL] [Abstract][Full Text] [Related]
35. Soluble coxsackie- and adenovirus receptor (sCAR-Fc); a highly efficient compound against laboratory and clinical strains of coxsackie-B-virus.
Pinkert S; Dieringer B; Diedrich S; Zeichhardt H; Kurreck J; Fechner H
Antiviral Res; 2016 Dec; 136():1-8. PubMed ID: 27773751
[TBL] [Abstract][Full Text] [Related]
36. Characterization of echoviruses that bind decay accelerating factor (CD55): evidence that some haemagglutinating strains use more than one cellular receptor.
Powell RM; Schmitt V; Ward T; Goodfellow I; Evans DJ; Almond JW
J Gen Virol; 1998 Jul; 79 ( Pt 7)():1707-13. PubMed ID: 9680134
[TBL] [Abstract][Full Text] [Related]
37. [The expression of coxsackie B virus adenovirus receptor (CAR) in viral myocarditis and dilated cardiomyopathy patients].
Li HY; Li YH; Zhu TJ
Fa Yi Xue Za Zhi; 2007 Aug; 23(4):247-9. PubMed ID: 17896511
[TBL] [Abstract][Full Text] [Related]
38. Endogenous low-level expression of the coxsackievirus and adenovirus receptor enables coxsackievirus B3 infection of RD cells.
Carson SD; Kim KS; Pirruccello SJ; Tracy S; Chapman NM
J Gen Virol; 2007 Nov; 88(Pt 11):3031-3038. PubMed ID: 17947527
[TBL] [Abstract][Full Text] [Related]
39. Hepatic damage caused by coxsackievirus B3 is dependent on age-related tissue tropisms associated with the coxsackievirus-adenovirus receptor.
Liu JY; Wang SM; Chen IC; Yu CK; Liu CC
Pathog Dis; 2013 Jul; 68(2):52-60. PubMed ID: 23620416
[TBL] [Abstract][Full Text] [Related]
40. Attachment of coxsackievirus B3 variants to various cell lines: mapping of phenotypic differences to capsid protein VP1.
Schmidtke M; Selinka HC; Heim A; Jahn B; Tonew M; Kandolf R; Stelzner A; Zell R
Virology; 2000 Sep; 275(1):77-88. PubMed ID: 11017789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
